#United States #New York #Levi Korsinsky #MoonLake #MLTX

MoonLake Immunotherapeutics Faces Lawsuit Over Alleged Securities Violations

In a significant development for shareholders, MoonLake Immunotherapeutics, listed under the ticker symbol MLTX on NASDAQ, is embroiled in a class action lawsuit concerning alleged securities law violations. The legal representation for the investors, Levi & Korsinsky, LLP, has taken the initiative to alert affected individuals regarding their rights and the potential for recovery of losses incurred during a specific period of alleged misconduct.

Background of the Case

The lawsuit targets investors who faced financial setbacks due to claims of securities fraud perpetrated between March 10, 2024, and September 29, 2025. Stakeholders believed their investments were bolstered by the company's claims surrounding its primary drug candidate, SLK, which was touted for its innovative Nanobody structure. However, details emerging from the filed complaint suggest serious discrepancies in the company’s public statements.

The allegations cite that MoonLake misled investors regarding several crucial aspects of SLK:
1. False Promises: The company allegedly conflated SLK with BIMZELX, suggesting both shared equivalent molecular targets, which may have misled stakeholders about SLK's efficacy.
2. Clinical Benefits: There's dispute over whether SLK's unique structure would genuinely confer advantages over more traditional treatments represented by BIMZELX, raising doubts about the viability of their claims.
3. Efficacy Assumptions: The assertion that SLK would demonstrate superior clinical benefits due to increased tissue penetration is now under scrutiny, suggesting promoters lacked credible reasoning for their optimistic projections.
4. Investor Misrepresentation: These false statements allegedly influenced investor decisions and fostered unwarranted confidence in the stock’s potential.

What Investors Need to Know

Affected investors have until December 15, 2025, to express their interest in participating in the class action and potentially serve as lead plaintiff, although participation does not necessitate lead plaintiff status for recovery. Levi & Korsinsky stresses that there are no costs incurred for those who join the case. Class members could stand to claim compensation without upfront fees.

If you find yourself among this group, further details and assistance are readily available from the law firm. Investors are encouraged to reach out to Levi & Korsinsky via their direct email or phone line to assess eligibility and discuss claims.

Why Levi & Korsinsky?

Levi & Korsinsky has established a formidable reputation in the realm of securities litigation over the past two decades. With a proven track record of recovering over hundreds of millions of dollars for investors, the firm’s team consists of more than 70 seasoned professionals committed to navigating the complexities of securities laws. Their consistent recognition, ranking among the Top 50 securities litigation firms in the U.S for seven consecutive years, assures clients of their expertise and dedication.

Contacting the Firm

For those interested in pursuing their rights and joining the class action, the following contact details for Levi & Korsinsky are provided:

• - Address: 33 Whitehall Street, 27th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

In summary, the ongoing legal proceedings against MoonLake Immunotherapeutics serve as a reminder of the volatility associated with stock investments and the importance of being vigilant against misleading corporate communications. Investors are urged to stay informed and act prudently to safeguard their financial interests amid such turbulent circumstances.